Diabetes & aspirin
This article was originally published in The Tan Sheet
Nearly half of American adults with diabetes are not using aspirin therapy to reduce their risk of recurrent heart attack or stroke, nor have they discussed such therapy with their physician, according to a survey released Nov. 21 by the American College of Preventive Medicine. Results were drawn from an eight-day online survey of 1,299 consumers over the age of 40 that was conducted in October 2004. The survey was conducted by Harris Interactive and was supported by an unrestricted educational grant from Bayer Healthcare. Approximately 15% of the respondents indicated they have diabetes, which places them at higher risk of cardiovascular-related events, according to the American Diabetes Association. While nearly half of the group with diabetes considered themselves "extremely knowledgeable" about aspirin, only 25% agreed that "the benefits of aspirin therapy strongly outweigh the risks"...
You may also be interested in...
Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty
The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.